+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Migraine Drugs Market - Global Forecast 2026-2032- Product Image
Migraine Drugs Market - Global Forecast 2026-2032- Product Image
New

Migraine Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968814
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The migraine drugs market is in transition, driven by evolving patient needs, new scientific breakthroughs, and shifted access pathways. Senior decision-makers navigating this sector must anticipate change and act quickly to sustain relevance as the landscape grows more complex.

Market Snapshot: Migraine Drugs Market Growth and Forecast

The migraine drugs market is projected to expand from USD 1.40 billion in 2025 to USD 1.49 billion in 2026, reaching USD 2.46 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 8.34%, indicating rising demand for both acute and preventive migraine treatments. Industry momentum is shaped by ongoing scientific innovation, such as mechanism-targeted therapeutics, as well as by factors like changing reimbursement models, shifting patient expectations, and greater access to new therapies. The interplay of innovation and market dynamics continues to shape opportunities and challenges for established players and new entrants alike.

Scope & Segmentation

The report offers actionable and comprehensive analysis designed to support strategic planning, competitive intelligence, and risk management. Key segmentation dimensions covered include:

  • Drug Classes: Covers CGRP monoclonal antibodies, triptans, gepants, ditans, NSAIDs, and ergot derivatives, with insights into evolving treatment roles and different impacts on patient outcomes.
  • Routes of Administration: Assesses intravenous, subcutaneous, oral, nasal, topical, and transdermal formulations, analyzing how urgency and patient choice influence therapy selection and adherence.
  • Distribution Channels: Explores both offline and online access, focusing on procurement practices, regulatory requirements, and adherence supports for patients and providers.
  • Indications: Evaluates acute and preventive care, clinical endpoints, payer criteria, and the influence on market access and reimbursement strategies.
  • Age Cohorts: Examines adults, adolescents, children, and neonates, detailing safety, efficacy, and dosing factors across life stages.
  • Regions: Analyzes the Americas, Europe, Middle East & Africa, and Asia-Pacific, identifying regulatory environments, payer trends, and healthcare infrastructure considerations affecting commercialization approaches.
  • Technologies: Highlights biologic mechanism-specific agents, novel delivery platforms, digital health tools, and integrated patient support systems in advancing care and operational efficiency.

Migraine Drugs Market: Key Takeaways for Senior Decision-Makers

  • Targeted therapies are establishing new benchmarks for effectiveness by focusing on disease mechanisms and patient-centric outcomes, surpassing the limitations of older analgesic approaches.
  • Emerging delivery systems, such as advanced biologics and innovative oral or nasal solutions, are broadening patient access and supporting uninterrupted care, especially where rapid relief is necessary.
  • Digital health tools are playing a larger role in improving patient engagement, enabling quicker diagnosis, bolstering adherence, and offering real-time monitoring for both acute and preventive regimens.
  • Increasing regulatory and payer complexity means that value-based contracts and real-world evidence are shaping market access, pricing, and formulary strategies.
  • Lifecycle management, through new indications and novel formulations, is essential for differentiation and long-term market presence as competitive pressures rise.

Tariff Impact on Value Chain Resilience

Recent tariff changes in the U.S. migraine therapeutics market have raised import costs, prompting manufacturers to evaluate nearshoring and domestic production as value chain resilience tactics. In response, organizations are enhancing scenario planning, diversifying supply networks, and tightening cold-chain logistics to limit possible disruptions. Adjustments in procurement strategies and payer negotiations reflect the new cost structures and evolving supply conditions.

Migraine Drugs Market Methodology & Data Sources

This research incorporates a mixed-methods framework, combining stakeholder interviews from clinical, payer, and supply chain experts with triangulated data from clinical trials, regulatory filings, and real-world studies. Peer-reviewed literature, industry analyses, and logistics data underpin all cross-sectional and longitudinal market assessments to ensure findings are robust and validated.

Migraine Drugs Market: Why This Report Matters

  • Supports alignment of clinical, commercial, and operations priorities for leadership teams through a unified, data-driven market viewpoint.
  • Guides strategic decisions for portfolio managers, commercial leads, and operations teams in adapting to regulatory changes, payer demands, and regional expansion.
  • Delivers investment and lifecycle management insights needed to capitalize on market innovation, mitigate risk, and drive sustainable value.

Conclusion

The migraine drugs market demands agile leadership as innovation and commercial factors accelerate. This report empowers decision-makers to pursue opportunities and manage complexity across drug development and delivery systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Migraine Drugs Market, by Drug Class
8.1. Cgrp Monoclonal Antibodies
8.1.1. Eptinezumab
8.1.2. Erenumab
8.1.3. Fremanezumab
8.1.4. Galcanezumab
8.2. Ditans
8.3. Ergot Derivatives
8.3.1. Dihydroergotamine
8.3.2. Ergotamine
8.4. Gepants
8.4.1. Atogepant
8.4.2. Rimegepant
8.4.3. Ubrogepant
8.5. Nsaids
8.5.1. Diclofenac
8.5.2. Ibuprofen
8.5.3. Naproxen
8.6. Triptans
8.6.1. Almotriptan
8.6.2. Eletriptan
8.6.3. Frovatriptan
8.6.4. Naratriptan
8.6.5. Rizatriptan
8.6.6. Sumatriptan
8.6.7. Zolmitriptan
9. Migraine Drugs Market, by Types
9.1. Injectable
9.1.1. Intravenous
9.1.2. Subcutaneous
9.2. Nasal
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
9.4. Topical
9.5. Transdermal
10. Migraine Drugs Market, by Indication
10.1. Acute Treatment
10.2. Preventive Treatment
11. Migraine Drugs Market, by Patient Age Group
11.1. Adult
11.2. Pediatric
11.2.1. Adolescents
11.2.2. Children
11.2.3. Neonates
12. Migraine Drugs Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Migraine Drugs Market, by End User
13.1. Hospitals & Clinics
13.2. Home Care Settings
13.3. Specialty Centers
14. Migraine Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Migraine Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Migraine Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Migraine Drugs Market
18. China Migraine Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Abbott Laboratories
19.6. AbbVie Inc.
19.7. Amgen Inc.
19.8. AstraZeneca PLC
19.9. Bausch Health Companies Inc.
19.10. Dr. Reddy’s Laboratories Ltd.
19.11. Eisai Co., Ltd.
19.12. Eli Lilly and Company
19.13. GlaxoSmithKline plc
19.14. H. Lundbeck A/S
19.15. Impel Pharmaceuticals Inc.
19.16. Johnson & Johnson
19.17. Merck & Co., Inc.
19.18. Novartis AG
19.19. Pfizer Inc.
19.20. Sanofi S.A.
19.21. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 165. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 168. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 182. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 183. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 197. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 198. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. EUROPE MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. EUROPE MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 218. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 219. EUROPE MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 220. EUROPE MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 221. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 222. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 223. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 224. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 225. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 226. EUROPE MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 227. EUROPE MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 228. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. EUROPE MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 232. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 233. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 234. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 235. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 236. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 242. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 243. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 246. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 247. AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 248. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 249. AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 250. AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 251. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 252. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 253. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 254. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 255. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 256. AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 257. AFRICA MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 258. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 259. AFRICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 263. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 264. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 265. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 266. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 267. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 268. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 269. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 270. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 271. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 272. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 273. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 274. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 275. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 276. ASEAN MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 278. ASEAN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 279. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 280. ASEAN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 281. ASEAN MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 282. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 283. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 284. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 285. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 286. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 287. ASEAN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 288. ASEAN MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 289. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 290. ASEAN MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. GCC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 292. GCC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 293. GCC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 294. GCC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 295. GCC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 296. GCC MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 297. GCC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 298. GCC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 299. GCC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 300. GCC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 301. GCC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 302. GCC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 303. GCC MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 304. GCC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 305. GCC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. BRICS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 322. BRICS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 323. BRICS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 324. BRICS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 325. BRICS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 326. BRICS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 327. BRICS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 328. BRICS MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 329. BRICS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 330. BRICS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 331. BRICS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 332. BRICS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 333. BRICS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 334. BRICS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 335. BRICS MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 336. G7 MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 337. G7 MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 338. G7 MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 339. G7 MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 340. G7 MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 341. G7 MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 342. G7 MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 343. G7 MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2018-2032 (USD MILLION)
TABLE 344. G7 MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 345. G7 MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 346. G7 MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 347. G7 MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 348. G7 MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 349. G7 MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 350. G7 MIGRAINE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 351. NATO MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 352. NATO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 353. NATO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 354. NATO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 355. NATO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2032 (USD MILLION)
TABLE 356. NATO MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
TABLE 357. NATO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2032 (USD MILLION)
TABLE 358. NATO MIGRAINE

Companies Mentioned

The key companies profiled in this Migraine Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Impel Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.46 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Acute Migraine Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Acute Migraine Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033 - Product Image

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

  • Report
  • 123 Pages
  • Global
From
Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Migraine Drugs - Global Strategic Business Report - Product Image

Migraine Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From

About the Migraine Drug Market

The Migraine Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Migraine drugs are used to treat the symptoms of migraine headaches, such as nausea, vomiting, and sensitivity to light and sound. These drugs can be divided into two categories: abortive and preventive. Abortive drugs are taken at the onset of a migraine attack to reduce the severity of symptoms, while preventive drugs are taken on a regular basis to reduce the frequency of migraine attacks. Common abortive drugs include triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs (NSAIDs). Common preventive drugs include beta-blockers, anticonvulsants, and serotonin receptor agonists. Some companies in the Migraine Drug market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Allergan. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.